Standing together against dementia
Dementia Over 46 million people worldwide are affected by dementia and by 2030 that number is expected to rise to 75 million.
The challenge of discovering new dementia medicines is too big for a single organisation to tackle independently, so the Dementia Consortium was formed to advance new treatments for dementia arising from academic research. The Consortium is an alliance between pharmaceutical companies (AbbVie, Astex, Eisai, Lilly and MSD) and medical research charities (Alzheimer’s Research UK and LifeArc). It is driven by the collective desire to urgently deliver new dementia medicines to patients; so far it has evaluated 84 research projects and seven of these are currently being developed.
Offering more attractive drug candidates
The Dementia Consortium fills a gap in the early stages of medicines discovery where little is really understood about the mechanisms of neurodegeneration. The Consortium funds research that increases our understanding of the brain and how to slow or arrest the progression of dementia. In doing so, the Consortium is able to create better validated and more attractive scientific data that the pharmaceutical industry can use to accelerate the development of new dementia medicines.
Global search for most promising science
The Consortium seeks to combine its experience, drawn from industry and LifeArc’s Centre for Therapeutics Discovery, with the best science from researchers globally. So far the Consortium has:
- Developed compounds to target inflammasomes (responsible for activation of inflammatory processes) called NLRP3, thought to be a main contributor to the nerve cell damage seen in Alzheimer’s disease.1
- Stimulated adult brain repair by inhibiting the protein TRIM32, which promotes neuronal stem cell proliferation.2
- Investigated whether the immune system regulator, fractalkine, offers protection against inflammation and cell death.3
- Explored clearing the build-up of a misfolded protein called TDP-43, which is thought to play a role in neuronal death.4
- Studied blocking the CSF1R protein to dampen the inflammatory response in the brain which could prevent disease progression.5
1 University of Manchester
2 University of Luxembourg
3 University of South Florida
4 ICGEB, Italy
5 University of Southampton